投资者关系活动记录表 证券代码：301166 证券简称：优宁维 编号：2022-01-01 上海优宁维生物科技股份有限公司 | --- | --- | --- | --- | |------------------------|-------------------------------------------------------------------------|----------------------------------------|-------------------------------| | 投资者关系活动类别 | | 特定对象调研 | 媒体采访 | | | | 业绩说明会 | 新闻发布会 | | | 路演活动 | | 现场参观 | | | | 其他电话采访 | 分析师会议 | | 来访单位名称及人员姓名 | 广发基金 | | 罗佳荣、孔令岩、田鑫 | | | 东证资本 | | 江琦、刘中群、谭鹏万 | | | 中信证券 海通证券 万家基金 高毅资产 交银基金 招商证券 | 彭聘 杨梦朝 刘慧敏、罗鸣 朱亦宁 方秋实 | 韩世通、陈竹、于聪、王凯旋 | | | 中信医药 | 韩世 ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-014 | --- | --- | |---------------------|------------------------------------| | 投资者关系活动 类别 | 分析师会议 业绩说明会 路演活动 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 参与单位名称及 | | | 人员姓名 | | | | | | | | | | | | | 程海泳 | | | | | | | | | | | --- | --- | |----------------------------------|--------| | | | | 深圳前海互兴资产管理有限公司 | 刘家将 | | 深圳景泰利丰投资 邹军辉 | | | 亘曦资产 林娟 | | | 观富（北京） 杨洁 | | | 固禾资产 王生瑞 | | | 太平洋 盛丽华 | | | 凯石基金管理有限公司 吴蔽野 | | | 深圳正圆投资 钟晓琳 | | | 金鹰基 ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-011 | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Group 1: Investor Relations Activities - The report includes various investor relations activities such as analyst meetings, performance briefings, and roadshows [2][3] - Specific participants from different asset management companies and investment firms were involved in the activities [2][3] Group 2: Impact of COVID-19 - The COVID-19 pandemic has negatively affected the company's operations, particularly due to school closures and lockdowns in Shanghai [3][4] - The company has implemented measures to mitigate the impact, including maintaining production and logistics operations during lockdowns [3][4] Group 3: Research Funding and Growth - Research funding in China is expected to maintain stable growth, with an average annual compound growth rate of 11.69% from 2012 to 2021 [3][4] - The company plans to continue investing in research and development, particularly in self-owned brands and products [4] Group 4: Financial Performance - In 2021, the company's revenue from self-owned brands "Absin" and "LabEx" reached 51.16 million yuan, a year-on-year increase of 124.26% [4] - The company's gross margin was 23% in 2021, with plans to improve it through enhanced product offerings and market share [4]

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-013 | --- | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------| | 投资者关系活动 类别 | 特定对象调研 媒体采访 新闻发布会 现场参观 其他 ( 电话会议) | | | | 光大证券 曹聪聪 | | | | 光大证券 林小伟 | | | | 光大证券 黎一江 | | | | 东海基金 王靖予 | | ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-015 | --- | --- | --- | |---------------------|----------------------------------------------------------------------------|-------------------------------------------| | 投资者关系活动 类别 | 特定对象调研 \n 媒体采访 新闻发布会 现场参观 其他 ( 电话会议) \n龙航资产 | 分析师会议 \n 业绩说明会 路演活动 \n | | | 辰翔投资 | | | | 中加基金 | | | | 西部研发 | | | | 西部研发 | | | | 华泰自营 | | | | 汐泰投资 | | | | 中信资管 | | | | 华泰证券资管 | | | | 光大自营 | | | 参与单位名称及 | 相聚资本 | | | 人员姓名 | 光证资管 | | | | 中融基金 | | | | 东证融汇资管 | 刘伟刚 | | | 上投摩根基金 ...

证券代码：301166 证券简称：优宁维 投资者关系活动记录表 上海优宁维生物科技股份有限公司 编号：2022-012 | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-016 | --- | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-026 | --- | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Group 1: Company Overview - Shanghai Youningwei Biotechnology Co., Ltd. focuses on life sciences and has established a nationwide direct sales channel to reach end customers [1] - The company has a strong professional team with over 17 years of industry experience, which enhances its market insight and competitive edge [1] Group 2: Supplier and Market Dynamics - The company maintains stable relationships with major suppliers, with a low supplier concentration, minimizing risks from trade frictions [1] - The company’s self-owned brands, Aibixin and Lebeishi, have seen a revenue growth of 124% year-on-year in 2021, indicating a strong market demand [2] Group 3: Impact of COVID-19 - The pandemic has negatively impacted operations, particularly in regions with strict lockdowns, but the company has adapted by ensuring continuous production and supply chain management [2] - The company has implemented measures to mitigate the impact of COVID-19, including remote operations and enhancing online engagement [2] Group 4: Logistics and Distribution - The company has modernized its logistics system, utilizing third-party logistics for distribution and ensuring efficient management of product shelf life and traceability [3] - New warehouses in cities like Chengdu and Nanjing have been established to improve delivery efficiency and respond to customer needs more effectively [2] Group 5: Future Investments and Development - The company plans to invest 280 million yuan in the Nanjing R&D and production base, which is expected to enhance its product development capabilities [3] - Future focus areas include accelerating R&D for self-owned products, enhancing sales teams, and expanding logistics capabilities to improve service delivery [4]